A pair of identical phase III trials hit their endpoint targets using sustained-exposure ciprofloxacin (branded Auripro, formerly OTO-201) in pediatric patients with bilateral middle ear effusion – fluid buildup – requiring tympanostomy tube placement, and Otonomy Inc. remains on track for a new drug application (NDA) filing in the first quarter of next year.